Clinical trials: Viral Upper Respiratory Tract Infection
COVID-19
Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults
This is a randomized, double-blind, parallel-controlled, equivalence trial, for evaluation of safety and immunogenicity, and batch-to-batch consistency of a recombinant adenovirus type-5-vectored Covid-19 vaccine Convidecia in…
- Trial name
- NCT05313646
- Testing
- batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV
- Where
- China
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine
This is a randomized, open-label, parallel-controlled study to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) after…
- Trial name
- NCT05043259
- Testing
- inactive SARS-CoV-2 vaccine (Vero cell), Low dose aerosolized Ad5-nCoV, High dose aerosolized Ad5-nCoV
- Where
- China
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Acute Respiratory Infection, Asthma Exacerbations
Reusable Face Masks to Reduce Risk of Viral Respiratory Infections and Asthma Exacerbations
REMASK trial is a Trial within Cohort study (TwiCs), nested within the COVIDENCE UK longitudinal study. It has been designed to determine whether the offer of a free reusable, elastomeric face mask to adults with asthma and other…
- Trial name
- REMASK (NCT06885229)
- Testing
- FloMask - reuseable face mask
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Viral Infections of the Upper Respiratory Tract
Probiotics in Prevention of Common Cold
The objective of this study is to assess the benefit and tolerability of a probiotic product in subjects with increased susceptibility to common cold.
- Trial name
- NCT02013934
- Testing
- Probiotic
- Where
- Germany
- Volunteers
- 899 people, healthy volunteers welcome
- Sponsor
- Probi AB
COVID-19
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the…
- Trial name
- NCT05855408
- Testing
- Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Respiratory Syncytial Virus Infections
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
The study will evaluate the safety, tolerability, and immunogenicity of 3 dose levels of IN006 in healthy adults aged 18 Years and Above; of a revaccination of IN006 given approximately 12 months after the initial vaccination in…
- Trial name
- NCT06645665
- Testing
- Bivalent RSV Vaccine (IN006)
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
COVID-19
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is to evaluate the safety and immunogenicity of the SARS-CoV-2 protein subunit recombinant vaccine adjuvanted…
- Trial name
- NCT05228613
- Testing
- SARS-CoV-2 protein subunit recombinant vaccine, SARS-CoV-2 inactivated vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Lower Respiratory Tract Infection, Upper Respiratory Tract Infection
Antiviral Activity of Oral Probiotics
The aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed S. salivarius probiotic in a powder format.
- Trial name
- NCT05374070
- Testing
- Streptococcus salivarius K12 Powder 1 Billion colony forming units /g), Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included, Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)
- Where
- New Zealand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- John Hale
URTI - Viral Upper Respiratory Tract Infection, Prevention
Clinical Trial to Evaluate the Efficacy of a Probiotic Preparation in the Prevention of Upper Respiratory Tract Infections in Adults
Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper…
- Trial name
- NCT07091955
- Testing
- Lacticaseibacillus rhamnosus CRL1505
- Where
- Spain
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bioithas SL
SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection
Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.
- Conditions
- SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
- Trial name
- COVID-19 (NCT04815018)
- Where
- 4 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Pathnostics
COVID-19
Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the safety and immnunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above.
- Trial name
- NCT05552573
- Testing
- low-dose LYB001, Recombinant COVID-19 Vaccine (CHO Cell), high-dose LYB001
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Viral Upper Respiratory Tract Infection
ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)
This is a single center study to evaluate the pharmacokinetics of ARMS-I a formulation that incorporates cetylpyridinium chloride (CPC), administered once as a single dose of three sprays orally, followed by multiple dosing (3x…
- Trial name
- ARMS-I (NCT03026205)
- Testing
- ARMS-I
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
COVID-19
Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly
This is an open phase Ⅲ clinical trial of COVID-19 vaccine (Vero cell), inactivated manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate Immunogenicity and safety of a third dose at…
- Trial name
- NCT05398926
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19
Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above
This is a multi-center, case-driven, randomized, double-blinded, and placebo-controlled Phase Ⅲb clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate…
- Trial name
- NCT05156632
- Testing
- Medium-dosage COVID-19 Vaccine,Inactivated, High-dosage COVID-19 Vaccine,Inactivated
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Influenza, Human, Infections
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine.
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05875961
- Testing
- Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59
- Where
- 7 sites in United States, Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seqirus
COVID-19
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and…
- Trial name
- NCT04990544
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Respiratory Tract Infection, Smell Disorder
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
Background: Loss of the sense of smell can seriously affect a person's quality of life. The ability to smell can be damaged by many factors, including illnesses, injuries, and exposure to toxic chemicals.
- Conditions
- Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis
- Trial name
- NCT07149428
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Viral Respiratory Tract Infection, Influenza
Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract Infections
Viral respiratory tract infections (VRTI) are among the most common human illnesses, impacting billions globally. There is an unmet need to identify novel ways to detect, treat and prevent their spread.
- Trial name
- WE SENSE (NCT05290792)
- Testing
- Administration of FluMist (Live Attenuated Influenza Vaccine)
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Emily McDonald